|Buprenorphine Urine Rapid Test (Strip/cassette)
|25 or 50 tests
The BUP Rapid Test (Urine) is a rapid chromatographic immunoassay for the detection of Buprenorphine in human urine at a cut-off concentration of 10 ng/mL.
Materials Provided with BUP drug Rapid Test kit:
1. BUP Test Device
The test contains mouse monoclonal anti-Buprenorphine antibody-coupled particles and Buprenorphine-protein conjugate. A goat antibody is employed in the control line system.
2. Instructions for use
Materials required, not Provided:
1. Urine collection container
2. Timer or clock
BUP Rapid Test kit Background Information
Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex,™ Buprenex,™ Temgesic,™ and Suboxone™ which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/mL after therapeutic administration, but can range up to 20 ng/mL in abuse situations. The plasma half-life of Buprenorphine is 2-4 hours. While complete elimination of a single-dose of the drug can take as long as 6 days, the detection window for the parent drug in urine is thought to be approximately 3 days.
The BUP Rapid Test (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Buprenorphine in urine. The BUP Rapid Test (Urine) yields a positive result when Buprenorphine in urine exceeds 10 ng/mL.
BUP drug Rapid Test Principle
The BUP Rapid Test (Urine) is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody.
During testing, a urine specimen migrates upward by capillary action. Buprenorphine, if present in the urine specimen below 10 ng/mL, will not saturate the binding sites of antibody-coated particles in the test. The antibody-coated particles will then be captured by immobilized Buprenorphine conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Buprenorphine level exceeds 10 ng/mL because it will saturate all the binding sites of anti-Buprenorphine antibodies.
A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration lower than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear in the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.